Bacterin says study cites potential for OsteoSponge SC Bacterin International announced that The Journal of Foot & Ankle Surgery has published a study on the "Role of Demineralized Allograft Subchondral Bone in the Treatment of Shoulder Lesions of the Talus: Clinical Results with Two-Year Follow-up." This study followed the use of OsteoSponge SC in the treatment of medial shoulder lesions of the talus, with positive clinical outcomes at 2 years post-op. The OsteoSponge SC procedure has the potential to address defects associated with subchondral bone pathology, which includes failed microfracture procedures and other treatment modalities. The total estimated US market for knee and ankle microfractures in 2014 is approximately 410,000 procedures. Bacterin is the only company in this market with a product specifically positioned to address repair of the subchondral bone in treating these defects, and has demonstrated clinical evidence to support the unique approach.
NYSE MKT to commence delisting proceedings against Bacterin NYSE MKT announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Bacterin International Holdings - ticker symbol BONE - from NYSE MKT.